Translational Medical Oncology and Individualized Cancer Therapy

Ayala-de Miguel, P; Muñoz-Couselo, E; Gutiérrez-Sanz, L; Fernández, LA; Navarro-Pérez, V; Berciano-Guerrero, MA; García-Arroyo, F; de la Rosa, C; Cerezuela-Fuentes, P; Majem, M; Campos-Balea, B; Soria, A; Hernández-Marín, B; García-Castaño, A; Martin-Algarra, S; Marquez-Rodas, I.

Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801)

Clinical & Translational Oncology. 2025; 28: 320-329 No. of citations: 4 [doi:10.1007/s12094-025-04005-w]

Stecklein, SR; Martin, M; Villacampa, G; del Monte-Millan, M; Yoder, R; Pathak, H; Cobo, S; Brasó-Maristany, F; Alvarez, EL; Echavarría, I; Bueno-Muiño, C; Jerez, Y; Cebollero, M; Bueno, O; García-Saenz, JA; Moreno, F; Gómez, HL; Massarrah, T; Herrero, B; Paré, L; Marín-Aguilera, M; Buckingham, W; López-Tarruella, S; Villagrasa, P; Godwin, AK; Salgado, R; Prat, A; Sharma, P.

Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer

JNCI-Journal of the National Cancer Institute. 2025; 118: 354-359 No. of citations: 5 [doi:10.1093/jnci/djaf162]

Alfano, F; Navas, P; Lamata, P; García, KF; Ortuño, JE; Zamora, OB; Lizarraga, S; Santos, A; Pascau, J; Goicolea, JM; Ledesma-Carbayo, MJ.

Patient-specific visco-hyperelastic mechanical model for breast tumor localization in surgical planning

Bioengineering & Translational Medicine. 2025; 11(1): [doi:10.1002/btm2.70044]

Calles, A; Navarro, A; Uribe, BGDD; Colomé, EA; de Miguel, M; Alvarez, R; Arregui, M; Moreno, V; Rocha, P; Calvo, E; Ramon-Patino, J; de la Fuente, EC; Alcalá-López, D; Boix, O; Fernández-Pinto, M; Rodríguez-Morató, J; Palmero, R; Nadal, E; Jove, M; Felip, E.

Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study

Journal of Thoracic Oncology. 2025; 20(7): 969-982 No. of citations: 18 [doi:10.1016/j.jtho.2025.02.005]

Adrián SG; Pérez CI; Carmona-Bayonas A; Morán LO; Pérez JR; Del Prado PM; De Castro EM; Neria F; Pérez IF; De Herreros MG; Campos MC; Escobar IG; Balanyà RP; González DM; Fonseca PJ; García MEG; Cánovas MS; Langa JM; Segura PP; Vidal MJM; Martín AJM.

Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding.

HAEMATOLOGICA. 2025; 110(7): 1513-1522 No. of citations: 4 [doi:10.3324/haematol.2024.286152]

Vedovati, MC; Martín, AJM; Giustozzi, M; Jimenez-Fonseca, P; Becattini, C; del Prado, MPM; Dentali, F; Huisman, M; Cohen, AT; Bauersachs, R; Carmona-Bayonas, A; Agnelli, G.

Derivation and validation of the Caravaggio score for the risk stratification for recurrence in patients with cancer-associated venous thromboembolism

European Journal of Internal Medicine. 2025; 137: 67-72 No. of citations: 6 [doi:10.1016/j.ejim.2025.04.016]

Agrawal, YN; Fernandez-Martinez, A; Gil-Gil, M; Zielinski, C; Ruiz-Borrego, M; Ciruelos, EM; Munoz, M; Margeli, M; Bermejo, B; Anton, A; Kahan, Z; Csoeszi, T; Alonso-Romero, JL; Garcia-Saenz, JA; Sanchez-Rovira, P; Alvarez, E; Chacon, JI; Gonzalez-Santiago, S; Rodriguez, CA; Servitja, S; Pfefferle, AD; Herranz, J; Liu, Y; Carey, LA; Romero-Camarero, I; Caballero, R; Guerrero-Zotano, A; Perou, CM; Martin, M.

Transcriptomic Predictors of Survival for Palbociclib plus Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial

JCO Precision Oncology. 2025; 9: [doi:10.1200/PO-24-00937]

Loibl, S; Martin, M; Bonnefoi, H; Untch, M; Kim, SB; Bear, HD; García-Sáenz, JA; Olivé, MM; Mc Carthy, N; Gelmon, K; Kelly, CM; Im, SA; Reimer, T; Martinez-Janez, M; Zhang, Z; Toi, M; Provencher, L; Rugo, HS; Gnant, M; Makris, A; Torres, AA; Hirmas, N; Holtschmidt, J; Nekljudova,; Marmé, F.

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HRD/HER2L breast cancer and residual disease after neoadjuvant chemotherapy

ANNALS OF ONCOLOGY. 2025; 36(7): 832-837 No. of citations: 19 [doi:10.1016/j.annonc.2025.03.010]

Felip, E; Rojas, CI; Schenker, M; Kowalski, DM; Casarini, IA; Csöszi, T; Sendur, MAN; Martins, J; Blanco, AC; Wang, C; Wang, M; Fallas, RALR; Yoshioka, H; Nair, S; Song, X; Deng, X; Lala, M; Eiras, R; Takahashi, T.

Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial

ANNALS OF ONCOLOGY. 2025; 36(7): 775-785 No. of citations: 44 [doi:10.1016/j.annonc.2025.03.012]

Chi, KN; Mckay, RR; Sandhu, S; Arranz, JA; Barthelemy, P; Hadaschik, B; Matsubara, N; Shore, ND; Ye, DW; Cascella, T; Irincheeva, I; Kreiser, S; Thiery-Vuillemin, A; Rathkopf, DE.

rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC

Future Oncology. 2025; 21(14): 1771-1777 No. of citations: 14 [doi:10.1080/14796694.2025.2502318]

Calles A; Calvo E; Santamaría Nuñez G; Costanzo F; Guillén MJ; Martinez Diez M; Gupta A; Cuevas C; Egly JM; Aviles P.

Unveiling the Mechanism of Lurbinectedin's Action and Its Potential in Combination Therapies in Small Cell Lung Cancer.

MOLECULAR CANCER THERAPEUTICS. 2025; 24(6): 828-839 No. of citations: 11 [doi:10.1158/1535-7163.MCT-24-0050]

Martín, AJM; Castet, F; Alsar, JS; Adeva, J; Peinado, P; Graña, B; Díaz, IA; Rodríguez-Alonso, RM; de Mena, ML; Vera, R; de Mena, IR; Aguilar, S; Vega, S; Morán, LO; Macarulla, T.

MDM2 amplification in a real-world cohort of patients with biliary tract cancer from the Spanish RETUD gastrointestinal registry

ESMO Gastrointestinal Oncology. 2025; 8: 100187-100187 No. of citations: 1 [doi:10.1016/j.esmogo.2025.100187]

Yu EY; Ferrario C; Linch MD; Stoeckle M; Laguerre B; Arranz JA; Todenhöfer T; Fong PC; Piulats JM; Berry W; Emmenegger U; Mourey L; Joshua AM; Mar N; Appleman LJ; Conter HJ; Gravis G; Li XT; Schloss C; Poehlein C; de Bono JS.

Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D.

European Urology Oncology. 2025; 8(3): 641-651 No. of citations: 7 [doi:10.1016/j.euo.2024.05.013]

Shinn, E; Zahrieh, D; DeMichele, A; Zdenkowski, N; Lemieux, J; Mao, J; Bjelic-Radisic, V; Naughton, MJ; Pfeiler, G; Gelmon, K; Balko, JM; Egle, D; Zoppoli, G; Traina, T; Jimenez, MM; Novoa, SA; Haddad, T; Chan, A; Ring, A; Wolff, A; Symmans, WF; Lorenzo, JP; Sabanathan, D; Burstein, HJ; Nowecki, ZI; Pristauz-Telsnigg, G; Brufsky, A; Bellet-Ezquerra, M; Foukakis, T; Novik, Y; Rubovszky, G; Singer, CF; Muehlbacher, K; Metzger, O; Goulioti, T; Law, E; Partridge, AH; Carey, LA; Zoroufy, A; Hlauschek, D; Fesl, C; Mayer, EL; Gnant, M.

Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer

BREAST CANCER RESEARCH AND TREATMENT. 2025; 211(2): 385-397 No. of citations: 1 [doi:10.1007/s10549-025-07653-2]

Pelegrín-Mateo, FJ; Zambrano, CB; Vázquez, EB; Escobar, IG; Martín, AM.

Cancer genetic profile and risk of thrombosis

European Journal of Internal Medicine. 2025; 136: 19-26 No. of citations: 10 [doi:10.1016/j.ejim.2025.04.004]

Fasching, PA; Slamon, D; Nowecki, Z; Kukielka-Budny, B; Stroyakovskiy, D; Yardley, DA; Huang, CS; Chan, A; Chia, S; Martín, M; Rugo, HS; Loi, S; Hurvitz, S; Untch, M; Afenjar, K; Fresco, R; Danyliv, A; Ferrusi, I; Li, Z; Hortobagyi, G.

Health-Related Quality of Life in Patients with HR+/HER2-Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial

CLINICAL CANCER RESEARCH. 2025; 31(9): 1625-1635 No. of citations: 10 [doi:10.1158/1078-0432.CCR-24-1724]

Besse, B; Goto, K; Wang, YS; Lee, SH; Marmarelis, ME; Ohe, Y; Bernabe, R; Kim, DW; Lee, JS; Cousin, S; Ichihara, E; Li, YS; Paz-Ares, L; Ono, A; Sanborn, RE; Watanabe, N; de Miguel, MJ; Helissey, C; Shu, CA; Spira, AI; Tomasini, P; Yang, JCH; Zhang, YP; Felip, E; Griesinger, F; Waqar, SN; Calles, A; Neal, JW; Baik, CS; Jaenne, PA; Shreeve, SM; Curtin, JC; Patel, B; Gormley, M; Lyu, X; Chen, J; Chu, PL; Mahoney, J; Trani, L; Bauml, JM; Thayu, M; Knoblauch, RE; Cho, BC.

Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A

Journal of Thoracic Oncology. 2025; 20(5): 651-664 No. of citations: 39 [doi:10.1016/j.jtho.2024.12.029]

Varela, M; Teixidó, C; Alvarez-Fernández, C; Arasanz, H; Peralta, S; Lázaro, M; Calvo, V; Alvarez, R; Baena, J; Valdivia, J; Arriola, E; Bernabé, R; Isla, D; Camacho, C; Massutí, B; Blasco, A; García, T; Cobo, M; Campayo, M; Hijazo-Pechero, S; Callejo, A; Dominguez, M; Nadal, E.

Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study

Translational Lung Cancer Research. 2025; 14(4): No. of citations: 5 [doi:10.21037/tlcr-2024-1146]